Home › To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher
 

Keywords :   


To sell or not to sell: United Therapeutics faces choice with potential fast-track drug voucher

2015-03-18 21:42:25| Biotech - Topix.net

Martine Rothblatt is the CEO of United Therapeutics Corp., which recently received Food and Drug Administration approval for its drug, Unituxin for treating pediatric patients with high-risk neuroblastoma. It also received a voucher that can be used to fast track a drug through the FDA's regulatory process.

Tags: united sell potential choice

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
07.11US cuts interest rates as Trump election raises uncertainty
07.11The Lehigh Short Course Website is Now Open
07.11Carbon Trust Verifies Four BASF Intermediates
07.11Atlantic Tropical Weather Outlook
07.11Eastern North Pacific Tropical Weather Outlook
07.11Labelink acquires International Label & Printing
07.11Pack Expo International sees record numbers in 2024
07.11Ahlstroms Climate Targets Validated by SBTi
More »